Outliers in Replicated Crossover Study [Outliers]

posted by ElMaestro  – Denmark, 2016-07-13 20:49 (2445 d 04:13 ago) – Posting: # 16487
Views: 18,446

Hello Pash413,

why bother?
I mean, the regardless of whether this value represents real life or not, I am not sure it changes anything for you. The matrix likelihood does change, but I don't think it has implications for the within subject variance for Ref, does it?
It is the latter that you can use for planning of new studies.

If the aberrant value is 'real' then it has implications for the point estimate, of course. But in a pilot study your sample is typically so small that you do not know the point estimate well (your CI's are big), therefore it might not at all be healthy to use the point estimate for anything. You can't make good decisions from the observed point estimate until the sample size is like in a pivotal trial. You can say that in a pivotal trial the sample size is so big that you can justify making a decision about the point estimate. It isn't when the sample size is pilot scale. It is almost a definition, but not one any company likes to discuss broadly.

Pass or fail!

Complete thread:

UA Flag
 Admin contact
22,550 posts in 4,724 threads, 1,606 registered users;
13 visitors (0 registered, 13 guests [including 5 identified bots]).
Forum time: 00:03 CET (Europe/Vienna)

That which is static and repetitive is boring.
That which is dynamic and random is confusing.
In between lies art.    John Locke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz